Peripheral immune features associated with severe adverse events in melanoma

Healy & Kovacsovics-Bankowski et al. SITC (2022)

Poster Highlights

  • Immune-related adverse events (irAEs) are major barriers to clinical management and further development of cancer immunotherapy.
  • We used mass cytometry to characterize the immune system before and during presentation of severe (grade 3+ that required clinical intervention) irAEs to identify cell signatures correlated with irAE development.
  • We found that patients with severe irAE have fewer immunosuppressive cells at baseline and more activated and tumor-reactive T cells during irAE presentation.
  • These findings suggest severe irAEs are the result of a lower baseline state of immunosuppression.

Download Poster PDF

Reference citation: Healy C, Kovacsovics M, Sigal N, et al. 44: Immune signatures of severe immune-related adverse events detected by mass cytometry immune profiling in blood in patients with advanced melanoma treated with immunotherapy. Journal for ImmunoTherapy of Cancer. 2022. doi: 10.1136/jitc-2022-SITC2022.0044

You Might Also Like